Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02151656
Other study ID # F17464 GE 2 01
Secondary ID 2013-005451-32
Status Completed
Phase Phase 2
First received May 28, 2014
Last updated December 15, 2016
Start date June 2014
Est. completion date December 2015

Study information

Verified date January 2016
Source Pierre Fabre Medicament
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santéFrance: Committee for the Protection of PersonnesHungary: Institutional Ethics CommitteeHungary: National Institute of PharmacyRomania: Ethics CommitteeRomania: National Agency for Medicines and Medical DevicesLithuania: Bioethics CommitteeLithuania: State Medicine Control Agency - Ministry of HealthLatvia: State Agency of MedicinesLatvia: Institutional Review BoardRussia: Ministry of Health of the Russian FederationRussia: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.


Recruitment information / eligibility

Status Completed
Enrollment 158
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

Demographic and other characteristics

- Male or female, 18-64 years of age inclusive

- primary diagnosis of schizophrenia undergoing an acute exacerbation with prominent "active phase" symptoms, as described by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM IV-TR) using the MINI 6.0 (Mini-International Neuropsychiatric Interview) for schizophrenia and psychotic disorders related to DSM IV-TR

- Well-documented diagnosis of schizophrenia for a minimum of 1 year before the screening visit

- Since the diagnosis of schizophrenia, the average number of hospitalisations should be no higher than 2 per year (the minimum duration of hospitalization should be more than 4 days)

- During the year before Visit 1, maximum 3 acute psychotic episodes that required hospitalization or change of antipsychotic medication or other therapeutic intervention

- Adequate clinical response to well-conducted treatment courses during previous acute episodes. A well conducted treatment course is defined as an antipsychotic treatment with the usual doses for at least 4 weeks

Current acute episode

- Structured Clinical Interview for the Positive And Negative Syndrome Scale (SCI-PANSS) with a PANSS total score = 70 to < 120 (at Visit 1 and 2)

- Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behaviour, conceptual disorganization, suspiciousness/persecution

- Clinical Global Impression of Severity (CGI-S) score = 4 (moderate or severe)

- Antipsychotic initiated for this acute episode and/or ongoing chronic antipsychotic treatment, with a maximum of 2 antipsychotics in total needed to be changed (due to inefficacy or safety reasons)

- Hospitalization and/ or treatment for the current psychotic episode for less than 2 weeks prior to Visit 1

- No significant improvement of PANSS total score between enrolment (Visit 1) and inclusion (Visit 2) corresponding to a score improvement < 20% on positive symptoms subscale

Exclusion Criteria:

Related to the pathology

- Patients in their first acute episode of psychosis

- Current schizophrenic episode with predominant negative symptoms

- Patient " known to be refractory " defined as lack of significant improvement (no significant relief of symptoms, and no period of good function) despite adequate courses with at least 3 different antipsychotics medication cycles of an adequate duration (at least 4 weeks) and at adequate dosage during the previous 5 years;

- Schizoaffective disorder, schizophreniform disorder and other psychotic disorders;

- Bipolar I and II disorder

- Pervasive developmental disorder, mental retardation, delirium, dementia, memory impairment and other cognitive disorders that would compromise a reliable assessment according to the investigator's opinion

- Known or suspected borderline or antisocial personality disorder or other DSM IV axis II disorder of sufficient severity to interfere with participation in this study

- History of tardive dyskinesia or chronic extra-pyramidal symptoms (EPS), serotonin syndrome or neuroleptic malignant syndrome

- Major depressive disorder which requires a pharmacological treatment

- At imminent risk of injuring him/herself or others or causing significant damage to property, as judged by the investigator

- Suicidal risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS)

- Any suicidal behavior in the past year

- Suicidal ideation of type 4 or 5 in the past month

Related to treatments

- Structured psychotherapy (e.g. cognitive behavioural therapy) started within 6 weeks before visit 1

- Electroconvulsive therapy within 3 months before Visit 1

- Previous lack of response to electroconvulsive therapy

- Treatment ongoing with a depot neuroleptic (even if less than 1 cycle in duration before Visit 1)

- Patient having previous treatment course with clozapine within the 4 months prior to Visit 1

- Requirement of concomitant treatment with any of the prohibited medications

- History of intolerance or hypersensitivity to other drugs of the same chemical class as F17464 or to rescue medications or any history of severe drug allergy or hypersensitivity

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
F17464

Placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pierre Fabre Medicament

Countries where clinical trial is conducted

France,  Hungary,  Latvia,  Romania,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the Positive and Negative Syndrome Scale (PANSS) total score Change from baseline to Day 43 of the PANSS total score Day 43 No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A